Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu Chief Technology Officer of Medicilon […]

Search Medicilon

Preclinical CRO

Medicilon’s Antibody-Peptide Conjugates Service Platform

Preclinical CRO

ACEA Pharma’s Ogrelvir Sodium Capsule Named in Nature’s 2025 Top Novel Target Drugs List with R&D Support from Medicilon

Preclinical CRO

Medicilon Supports Partner Nanolattix, Two RDC and ADC Studies Accepted for EANM’26; HER2/TF Bispecific Research Selected as Top-Rated Oral Presentation

Contact Medicilon

Name(Required)
Address(Required)